Newer antidiabetic agents, such as sodium-glucose cotransporter-2 (SGLT-2) inhibitors [219,220] and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) [221], decreased PWV in studies in patients with type-2 diabetes. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.